References
Kobinger W. Central alpha-adrenergic systems as targets for hypotensive drugs. Rev Physiol Biochem Pharmacol 1978;81:39–100.
van Zwieten PA, Thoolen MJ, Timmermans PB. The hypotensive activity and side effects of methyldopa, clonidine, and guanfacine. Hypertension 1984;6:II28–II33.
Reid JL, Wing LM, Mathias CJ, Frankel HL, Neill E. The central hypotensive effect of clonidine. Studies in tetraplegic subjects. Clin Pharmacol Ther 1977;21:375–381.
Koshiji M, Ito H, Minatoguchi S, et al. A comparison of guanfacine, bunazosin, atenolol and nadolol on blood pressure and plasma noradrenaline responses to cold pressor testing. Clin Exp Pharmacol Physiol 1992;19:481–488.
Prichard BN. Principles and practice of α − antiantiadrenergic therapy. In: Messerli FH, ed. Cardiovascular Drug Therapy, 2nd edition Philadelphia: WB Saunders Company, 1996:601–616.
Jarrott B. Clonidine and related compounds. In: Doyle AE, ed. Clinical Pharmacology of Antihypertensive Drugs, ed. Amsterdam: Elsevier Science Publishers BV, 1988:125–186. [Birkenhager WH, Reid JL, eds. Handbook of Hypertension, Vol 11.]
Aars H. Effects of clonidine on aortic diameter and aortic baroreceptor activity. Eur J Pharmacol 1972;20:52–59.
Shaw J, Hunyor SN, Korner PI. The peripheral circulatory effects of clonidine and their role in the production of arterial hypotension. Eur J Pharmacol 1971;14:101–111.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
de Leeuw, P.W. Clonidine—Revisited, Relived or Time for Further Investigations?. Cardiovasc Drugs Ther 19, 5–6 (2005). https://doi.org/10.1007/s10557-005-6897-z
Issue Date:
DOI: https://doi.org/10.1007/s10557-005-6897-z